Clinical Research Directory
Browse clinical research sites, groups, and studies.
Contributions to Hypertension With Androgen Deprivation Therapy
Sponsor: University of Colorado, Denver
Summary
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Official title: Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Key Details
Gender
MALE
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-09-20
Completion Date
2025-07-16
Last Updated
2026-09-02
Healthy Volunteers
Yes
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH)
8 weeks of GnRH agonist
Androgen receptor (AR) inhibitor
2 weeks of AR Inhibitor
Placebo
Placebo tablet and injection
Locations (1)
UCHealth University of Colorado Hospital
Aurora, Colorado, United States